» Articles » PMID: 18777956

Synergizing Radiation Therapy and Immunotherapy for Curing Incurable Cancers. Opportunities and Challenges

Overview
Specialty Oncology
Date 2008 Sep 10
PMID 18777956
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

The combination of radiation therapy and immunotherapy holds particular promise as a strategy for cancer therapeutics. Evidence suggests that immunotherapy is most beneficial alone when employed early in the disease process or in combination with standard therapies (eg, radiation) later in the disease process. Indeed, radiation may act synergistically with immunotherapy to enhance immune responses, inhibit immunosuppression, and/or alter the phenotype of tumor cells, thus rendering them more susceptible to immune-mediated killing. As monotherapies, both immunotherapy and radiation may be insufficient to eliminate tumor masses. However, following immunization with a cancer vaccine, the destruction of even a small percentage of tumor cells by radiation could result in crosspriming and presentation of tumor antigens to the immune system, thereby potentiating antitumor responses. Learning how to exploit radiation-induced changes to tumor-cell antigens, and how to induce effective immune responses to these cumulatively immunogenic stimuli, is an exciting frontier in cancer therapy research. This review examines mechanisms by which many forms of radiation therapy can induce or augment antitumor immune responses as well as preclinical systems demonstrating that immunotherapy can be effectively combined with radiation therapy. Finally, we review current clinical trials where standard-of-care radiation therapy is being combined with immunotherapy.

Citing Articles

The Tight Relationship Between the Tumoral Microenvironment and Radium-223.

Conte M, Tomaciello M, De Feo M, Frantellizzi V, Marampon F, De Cristofaro F Biomedicines. 2025; 13(2).

PMID: 40002869 PMC: 11853176. DOI: 10.3390/biomedicines13020456.


Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment.

Cheng C, Chang J, Ho A, Sie Z, Peng C, Wang C Cancer Immunol Immunother. 2024; 73(9):175.

PMID: 38953994 PMC: 11219622. DOI: 10.1007/s00262-024-03761-y.


Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma.

Oshima K, Tsushima T, Ito Y, Kato K Jpn J Clin Oncol. 2024; 54(4):395-402.

PMID: 38342589 PMC: 10999767. DOI: 10.1093/jjco/hyae005.


Chrysin Encapsulated Copper Nanoparticles with Low Dose of Gamma Radiation Elicit Tumor Cell Death Through p38 MAPK/NF-κB Pathways.

Abdelhakm L, Kandil E, Mansour S, El-Sonbaty S Biol Trace Elem Res. 2023; 201(11):5278-5297.

PMID: 36905557 PMC: 10509080. DOI: 10.1007/s12011-023-03596-1.


Radiotherapy enhances CXCR3CD8 T cell activation through inducing IFNγ-mediated CXCL10 and ICAM-1 expression in lung cancer cells.

Wang C, Ho A, Chang C, Sie Z, Peng C, Chang J Cancer Immunol Immunother. 2023; 72(6):1865-1880.

PMID: 36688994 PMC: 10198930. DOI: 10.1007/s00262-023-03379-6.


References
1.
Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L . Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2007; 15(1):3-12. DOI: 10.1038/sj.cdd.4402269. View

2.
Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile R . Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med. 1998; 4(5):581-7. DOI: 10.1038/nm0598-581. View

3.
Younes E, Haas G, Dezso B, Ali E, Maughan R, KuKuruga M . Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol. 1995; 165(2):243-51. DOI: 10.1006/cimm.1995.1211. View

4.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A . Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13(9):1050-9. DOI: 10.1038/nm1622. View

5.
Marshall J, Hoyer R, Toomey M, Faraguna K, Chang P, Richmond E . Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000; 18(23):3964-73. DOI: 10.1200/JCO.2000.18.23.3964. View